BOTANIX PHARMACEUTICALS

Botanix reported a record volume for Sofdra with 26,684 prescriptions delivered in the quarter and a monthly record in March, while net revenues temporarily fell from $9.1 million to $6.9 million due to the annual reset of deductibles in US health insurance plans. The GTN margin declined temporarily but is expected to normalize in the fourth quarter. The company strengthened its balance sheet with a $45 million capital raise, negotiated payment deferrals for API purchases, and signed a term-sheet agreement with Piramal that could reduce manufacturing costs by an estimated 25–40%. » Más en de.investing.com

Botanix reported a gross revenue of AUD 120 million over the past 12 months and delivered 26,684 prescriptions in Q3. The gross-to-net margin improved from 16% to 19% by quarter-end, and the pro forma cash position is AUD 50.8 million. The stock fell 5% after the release. Management expects further margin improvement in Q4; projected EPS: -0.02 USD (2026) and -0.01 USD (2027), revenue forecasts: 27.71 million USD (2026) and 56.43 million USD (2027). » Más en de.investing.com

Botanix reported Q2 FY2026 net revenue of $9.1m, driven by a 24% increase in Sofdra prescriptions versus the prior quarter. The gross-to-net margin improved to 24% but remains below the 30–40% target range. Operating cash outflow rose to $17.2m after expanding the field sales force and higher operating expenses, worrying investors and sending the stock down 6%. Botanix has $31.5m in cash and $14.9m in undrawn credit lines; the challenge remains controlling costs and improving margins toward profitability. » Más en de.investing.com